4.0 Article

A 1,536-well-based kinetic HTS assay for inhibitors of Schistosoma mansoni thioredoxin glutathione reductase

期刊

ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
卷 6, 期 4, 页码 551-555

出版社

MARY ANN LIEBERT INC
DOI: 10.1089/adt.2008.149

关键词

-

资金

  1. National Institutes of Health Roadmap for Medical Research
  2. Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health
  3. National Institutes of Health/National Institute of Mental Health [1R03MH076449]
  4. National institutes of Health/National Institute of Allergy and Infectious Diseases [5R01AI065622]

向作者/读者索取更多资源

Schistosomiasis is a major neglected tropical disease that currently affects over 200 million people and leads to over 200,000 annual deaths. Schistosoma mansoni parasites survive in humans in part because of a set of antioxidant enzymes that continuously degrade reactive oxygen species produced by the host. A principal component of this defense system has been recently identified as thioredoxin glutathione reductase (TGR), a parasite-specific enzyme that combines the functions of two human counterparts, glutathione reductase and thioredoxin reductase, and as such this enzyme presents an attractive new target for anti-schistosomiasis drug development. Herein, we present the development of a highly miniaturized and robust screening assay for TGR. The 5-mu l final volume assay is based on the Ellman reagent [5,5'-dithiobis(2-nitrobenzoic acid) (DTNB)] and utilizes a high-speed absorbance kinetic read to minimize the effect of dust, absorbance interference, and meniscus variation. This assay is further applicable to the testing of other redox enzymes that utilize DTNB as a model substrate.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据